Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Telegram Restored on Apple App Store After Temporary Removal 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
SAN DIEGO and TORONTO, April 03, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on Monday, April 9, 2018 at 11:30 a.m. CEST:
| Time: | 11:30 a.m. CEST | |||||
| Date: | Monday, April 9, 2018 | |||||
| Location: | Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco | |||||
| Live webcast: | http://wsw.com/webcast/hcw2/apto/ |
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: [email protected]
| SMP Communications Susan Pietropaolo 201-923-2049 [email protected] | LifeSci Advisors Michael Wood Managing Director 646-597-6983 [email protected] |
